Please assess the completion status of the following clinical trial:

Trial Title: Alprazolam as Conscious Sedation for Upper Gastrointestinal Endoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Referring for upper GI endoscopy~* Age 18 to 65 years~* First experience of upper GI endoscopy~* Class I or II of American Anesthesiology Association~* Willingness to participate~Exclusion Criteria:~* Severe psychiatric, neurological, cardio-vascular, or renal disorders~* History of allergy or intolerance to benzodiazepines or lidocaine~* History of upper GI surgery~* Pregnancy or lactation~* GI anomalia during endoscopy~* Need for therapeutic procedures during endoscopy~* Active bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Oral placebo (Type: PLACEBO_COMPARATOR): Patients receive one oral dose of placebo least 30 minutes before the procedure.
- Sublingual placebo (Type: PLACEBO_COMPARATOR): Patients receive one oral dose of placebo at least 30 minutes before the procedure.
- Sublingual alprazolam (Type: ACTIVE_COMPARATOR): Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.
- Oral alprazolam (Type: ACTIVE_COMPARATOR): Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).